Genomic Vision: 2014 Annual Revenue from Sales at €3.5 Million

Solid cash position of €22.8 million

Regulatory News:

Genomic Vision (Paris:GV) (FR0011799907 – GV / PEA-PME eligible), a molecular diagnostics company specialized in the development of diagnostic tests for genetic diseases and cancers based on molecular combing, today announces its revenue from sales and cash position¹ at December 31, 2014.

Revenue from sales for the 4^th quarter and full-year 2014

In thousands of euros		Q4 2014		2014		2013
Revenue from R&D Quest Diagnostics		361		3,218		2,655
Product sales		75		237		232
Total revenue from sales		435		3,455		2,887

Over the 4^th quarter of 2014, Genomic Vision recorded revenue from sales of €435 thousand. This essentially comprises revenue from the Company’s R&D collaboration with its American partner Quest Diagnostics, which totaled €361 thousand over the period, in line with the progress achieved within the framework of their collaboration. The €75 thousand in product sales came from sales of the CombHelix FSHD test carried out directly by Genomic Vision in France, at the Timone hospital in Marseille, royalties paid by Quest Diagnostics, which offers this test in its labs in the United States, and sales of consumables and instruments to research laboratories.

Over 2014 as a whole, revenue from sales totaled €3.5 million, compared with €2.9 million in 2013.

Cash and cash equivalents

At December 31, 2014, cash and cash equivalents totaled €22.8 million, compared with €24.8 million at September 30, 2014. This solid cash position reflects the Company’s strict management of its expenditure within a context of buoyant development.

Erwan Martin, Genomic Vision’s VP Finance & Corporate Development, comments:

“Our 2014 annual revenue from sales, consisting essentially of R&D revenue, is due to the reaching of some major milestones in our strategic collaboration with Quest Diagnostics, in line with our commitments. Indeed, the validation of a diagnostic test for Lynch Syndrome, a new protocol for the Genomic Morse Code and, more recently, the installation of the new high-throughput scanner with the protocol of the BRCA test at a Quest laboratory were all achieved on schedule. We therefore remain confident regarding the buoyant pursuance of our collaboration that, in 2015, should result in the launch of the BRCA test for detecting hereditary breast and ovarian cancer.”

Next financial press release

• 2014 full-year results, on April 30, 2015* (after market)

* Indicative date, subject to potential modifications

●●●

ABOUT GENOMIC VISION

Founded in 2004, Genomic Vision is a molecular diagnostics company specialized in the development of diagnostic tests for genetic diseases and cancers based on molecular combing. Using this innovative technology that allows the direct visualization of individual DNA molecules, Genomic Vision detects quantitative and qualitative variations in the genome that are at the origin of numerous serious pathologies. The Company is developing a solid portfolio of tests that notably target breast cancer and cancer of the colon. Since 2013, the Company has marketed the CombHeliX FSHD test for identifying a myopathy that is difficult to detect, Facio-scapulo-humeral dystrophy (FSHD), in the United States thanks to a strategic alliance with Quest Diagnostics, the American leader in diagnostic laboratory tests, and in France. Genomic Vision has been listed on Compartment C of Euronext Paris since April 2014.

ABOUT MOLECULAR COMBING

DNA molecular combing technology considerably improves the structural and functional analysis of DNA molecules. DNA fibers are stretched out on glass slides, as if “combed”, and uniformly aligned over the whole surface. It is then possible to identify genetic anomalies by locating genes or specific sequences in a patient’s genome using genetic markers, an approach developed by Genomic Vision and patented under the name Genomic Morse Code. This exploration of the entire genome at high resolution via a simple analysis enables the direct visualization of genetic anomalies that are undetectable by other technologies.

For further information, please go to www.genomicvision.com

Member of CAC® Mid & Small, CAC® All-Tradable and EnterNext© PEA-PME 150 indexes

DISCLAIMER

This press release contains certain forward-looking statements concerning Genomic Vision and its business.

Such forward-looking statements are based on assumptions that Genomic Vision considers to be reasonable. However, there can be no assurance that such forward-looking statements will be verified, which statements are subject to numerous risks, including the risks set forth in the prospectus on which the French Financial Market Authority (AMF) granted its visa n° 14-087 on March 19, 2014 and to the development of economic conditions, financial markets and the markets in which Genomic Vision operates. The forward-looking statements contained in this press release are also subject to risks not yet known to Genomic Vision or not currently considered material by Genomic Vision. The occurrence of all or part of such risks could cause actual results, financial conditions, performance or achievements of Genomic Vision to be materially different from such forward-looking statements.

This press release and the information contained herein do not constitute and should not be construed as an offer or an invitation to sell or subscribe, or the solicitation of any order or invitation to purchase or subscribe for GENOMIC VISION shares in any country. The distribution of this press release in certain countries may be a breach of applicable laws. The persons in possession of this press release must inquire about any local restrictions and comply with these restrictions.

¹ Unaudited data.